Main Menu

The technology involves the discovery and development of novel compounds that inhibit the plasmodial surface anion channel (PSAC), a promising drug target for malaria treatment. These compounds have been identified through high-throughput screening as specific and potent inhibitors of PSAC, effectively killing malaria parasite cultures by blocking nutrient acquisition from human plasma. Importantly, the compounds exhibit drug-like properties and show no cytotoxicity to other cells.

This technology encompasses the discovery of broadly neutralizing antibodies against HIV-1, derived from the CAPRISA Donor CAP 256. These antibodies target the V1V2 epitope of the virus envelope and exhibit a high level of neutralization, particularly against Clade A and Clade C subtypes.

The technology involves the development of a probiotic-based inhalational therapeutic for the prevention and treatment of acute respiratory virus infections. This innovative approach utilizes live or heat-inactivated cells of Lactobacillus plantarum, administered directly to the respiratory mucosa. This method has shown significant protection against lethal outcomes of respiratory virus infections by suppressing virus-induced proinflammatory cytokines.

This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).

The discovery of the S1-4-A09 antibody and its A80P derivative from a survivor of Ebola virus disease represents a significant advancement in the development of therapeutics against Ebola virus. These antibodies, isolated using innovative techniques, demonstrate potent antiviral activities in vitro and have shown improved stability and manufacturing feasibility compared to existing antibodies.

The technology offers a novel and efficient method for inducing targeted DNA recombination using a tripartite fusion protein, LFn-NLS-Cre, in combination with anthrax toxin protective antigen (PA). This system enables precise genetic manipulation in cells carrying a gene flanked by loxP sites, allowing for specific recombination events.

The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.

The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG).

The "Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation" is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration.

This technology presents a novel prime-boost vaccine strategy using recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors to protect against lentiviral infections, particularly HIV. The approach involves different prime-boost combinations with LCMV vectors expressing HIV proteins, demonstrating efficacy in eliciting immune responses.